News from IMIM
Hospital del Mar and IMIM participated in an international study that has analyzed the effects of Romosozumab on bones. It is a highly selective monoclonal antibody that potently activates bone forming cells, the osteoblasts. At the same time it suppresses cells that destry the bone, the osteoclasts. This joint action could not be achieved with other available drugs to treat osteoporosis, a disease in which bones become fragile and more likely to fracture. It occurs when the body is unable to produce enough new bone and/or when too much existing bone is reabsorbed.
"The currently available drugs act to prevent the loss of bone or to increase bone formation, but Rozosozumab is the first treatment combining both effects, and therefore, it is much more effective in increasing bone mineral density than any treatment that we have now," says Dr. Diez.
IMIM website (in Spanish and Catalan)
McClung MR , Grauer A, Boonen S , Bolognese MA , Brown JP , Díez- Pérez A, Langdahl BL , Reginster JY , Zanchetta JR , Wasserman SM , Katz L, Maddox J , Yang YC , Libanati C , Bone HG. Romosozumab in Postmenopausal Women with Low Bone Mineral Density. New Engl J Med 2014.